# US 2010/0167418 A1 · Stabilized low affinity conformation of integrins for drug discovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167418 A1
- Document ID: US20100167418A1
- Status: Published application
- Kind: A1
- Application number: 12/645,958
- Filed: 2009-12-23
- Published: 2010-07-01
- Earliest claimed: 2008-12-29
- Assignees: Immune Disease Institute, Inc.
- Inventors: Timothy A. Springer; Bing Hao Luo
- Web page: https://patentgrep.com/patent/US20100167418A1

## CPC

- G01N 33/5032: {on intercellular interactions}
- C07K 14/70546: {Integrin superfamily}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2333/70546: Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N 2333/70557: Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.

## Claims

### Claim 1

A method for identifying a candidate modulator of integrin activity, the method comprising (a) contacting an integrin polypeptide with a candidate agent, wherein the integrin polypeptide is locked into a desired conformation; and (b) detecting binding of the candidate agent to the integrin polypeptide, wherein binding of the candidate agent to the integrin polypeptide is indicative that the candidate agent is a candidate modulator of integrin activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the candidate agent is selected from the group consisting of an antibody, a small molecule, a chemical, a peptide, and a peptidomimetic.

### Claim 3 (depends on 1)

The method of claim 1, wherein the candidate modulator stabilizes the integrin polypeptide into a closed conformation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the candidate modulator inhibits binding of an integrin ligand to the integrin polypeptide.

### Claim 5 (depends on 1)

The method of claim 1, wherein the integrin polypeptide is selected from the group consisting of αVβ3, αIIbβ3, αVb6, αVβ1, αVβ5, αMβ2, αXβ2, αLβ2, and αVβ8.

### Claim 6 (depends on 1)

The method of claim 1, wherein locking the integrin polypeptide into the desired conformation comprises introducing a stabilizing disulfide bond into the integrin polypeptide.

### Claim 7 (depends on 6)

The method of claim 6, wherein the disulfide bond is formed by a cysteine residue substitution of at least one amino acid residue of the integrin polypeptide.

### Claim 8 (depends on 6)

The method of claim 6, wherein the substitution comprises a mutation selected from the group consisting of: L959C (human αIIb), E960C (human αIIb), 1955C (human αV), Q956C (human αV), V664C (human β3), P688C (human β3), L662C (human β6), P686C (human β6), A619C (human β8), and F636C (human β3).

### Claim 9 (depends on 8)

The method of claim 8, wherein an optimal sequence alignment is used to identify homologous residues for a cysteine substitution in an integrin polypeptide selected from the group consisting of αVβ3, αIIbβ3, αVb6, αVβ1, αVβ5, αMβ2, αXβ2, αLβ2, and αVβ8.

### Claim 10 (depends on 1)

The method of claim 1, wherein the candidate agent is assayed for activation or inhibition of integrin activity.

### Claim 11 (depends on 9)

The method of claim 9, wherein a cell-based assay is used to determine integrin activity.

### Claim 12

An integrin polypeptide composition comprising: a modified integrin polypeptide, wherein the integrin polypeptide is locked in a closed conformation.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the integrin polypeptide is modified by substitution of at least one amino acid residue for a cysteine residue, whereby a disulfide bond is formed.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the substitution comprises a mutation selected from the group consisting of: L959C (human αIIb), E960C (human αIIb), I955C (human αV), Q956C (human αV), V664C (human β3), P688C (human β3), L662C (human β6), P686C (human β6), A619C (human β7), and F636C (human β3).
